Stock listing

LS Exchange:A1CXBG AB Science SA Aktie

German listing (LS Exchange) of AB Science SA · home listing Euronext:AB

Follow AB Science SA into a list and get an email when it puts out news.

Home listing price · EURONEXT:AB

€0.521 EUR -0.043 (-7.6%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:AB

Past year -54.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
€0.520 – €0.562 EURNov 20, 2026
Volume
99,512 sharesNov 20, 2026
Market cap
€50.29M EURAt the close on Nov 20, 2026 · price × 96.53M shares outstanding
52-week range
€0.488 – €1.610 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€149,514 EURMedian day 144,917 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
AB Science SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Euronext:AB · Home€0.521 EUR-0.043 (-7.6%)99,512€0.562€0.562€0.520€0.564Close on Nov 20, 2026
LSE:0Q77€0.546 EUR-0.021 (-3.7%)2€0.546€0.546€0.546€0.567Close on Nov 20, 2026
Frankfurt:A8D€0.555 EUR-0.012 (-2.1%)—€0.555€0.555€0.555€0.567Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:AB · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.521-0.043-7.6%€0.562€0.562€0.52099,512
€0.564-0.006-1.1%€0.588€0.588€0.56487,133
€0.570-0.015-2.6%€0.582€0.593€0.567143,246
€0.585-0.040-6.4%€0.623€0.624€0.582140,549
€0.625-0.057-8.4%€0.690€0.690€0.615502,120
€0.682+0.062+10.0%€0.630€0.728€0.6301,255,051
€0.620+0.086+16.1%€0.551€0.620€0.540579,623
€0.534+0.024+4.7%€0.519€0.548€0.511198,833
€0.510+0.004+0.8%€0.500€0.518€0.50065,722
€0.506-0.021-4.0%€0.527€0.527€0.488502,499
€0.527-0.001-0.2%€0.528€0.536€0.52673,966
€0.5280.0000.0%€0.540€0.540€0.52667,483
€0.528-0.011-2.0%€0.539€0.539€0.52695,607
€0.539-0.002-0.4%€0.541€0.541€0.52985,207
€0.541-0.007-1.3%€0.544€0.547€0.53784,023
€0.548+0.006+1.1%€0.560€0.562€0.54234,087
€0.542+0.009+1.7%€0.540€0.570€0.536129,061
€0.533+0.003+0.6%€0.530€0.539€0.53022,201
€0.530-0.019-3.5%€0.547€0.554€0.52973,404
€0.549+0.006+1.1%€0.541€0.567€0.54149,499
€0.543-0.022-3.9%€0.566€0.569€0.54375,277
€0.565+0.015+2.7%€0.584€0.584€0.54488,107
€0.550+0.009+1.7%€0.536€0.558€0.53544,337
€0.541-0.002-0.4%€0.543€0.546€0.53260,975
€0.543-0.008-1.5%€0.544€0.570€0.540133,938
€0.551-0.009-1.6%€0.564€0.598€0.544345,166
€0.560-0.020-3.4%€0.576€0.582€0.556154,939
€0.580+0.031+5.6%€0.558€0.605€0.558419,375
€0.549+0.025+4.8%€0.526€0.564€0.526177,933
€0.524+0.009+1.7%€0.529€0.529€0.51647,147
€0.515-0.007-1.3%€0.520€0.549€0.508242,876
€0.522-0.023-4.2%€0.540€0.541€0.520137,266
€0.545+0.008+1.5%€0.570€0.570€0.545212,713
€0.537-0.007-1.3%€0.545€0.551€0.530112,852
€0.544-0.038-6.5%€0.580€0.586€0.539556,897
€0.582-0.008-1.4%€0.592€0.593€0.580266,124
€0.590+0.002+0.3%€0.600€0.611€0.590312,231
€0.588-0.102-14.8%€0.662€0.662€0.5801,315,141
€0.690+0.006+0.9%€0.690€0.700€0.68129,121
€0.684-0.009-1.3%€0.700€0.700€0.669162,941
€0.693-0.017-2.4%€0.708€0.714€0.693100,793
€0.710-0.002-0.3%€0.712€0.720€0.70858,102
€0.712-0.002-0.3%€0.710€0.724€0.709163,327
€0.714+0.009+1.3%€0.702€0.729€0.701149,744
€0.705-0.007-1.0%€0.720€0.729€0.70597,794
€0.712+0.003+0.4%€0.702€0.721€0.70240,846
€0.709+0.006+0.9%€0.702€0.722€0.70296,692
€0.703-0.017-2.4%€0.713€0.715€0.70182,909
€0.720-0.010-1.4%€0.725€0.727€0.700107,191
€0.730+0.025+3.5%€0.716€0.744€0.704318,136
€0.705-0.001-0.1%€0.729€0.729€0.70056,554
€0.706-0.026-3.6%€0.732€0.732€0.700210,761
€0.732+0.007+1.0%€0.730€0.749€0.730234,666
€0.725-0.007-1.0%€0.730€0.749€0.687222,035
€0.732-0.002-0.3%€0.734€0.734€0.720119,069
€0.734-0.006-0.8%€0.747€0.754€0.730146,587
€0.740+0.004+0.5%€0.739€0.769€0.721320,663
€0.736+0.033+4.7%€0.708€0.742€0.697259,437
€0.703-0.020-2.8%€0.710€0.717€0.692284,132
€0.7230.0000.0%€0.735€0.747€0.720250,769
€0.723+0.010+1.4%€0.706€0.748€0.706356,181
€0.713-0.026-3.5%€0.731€0.748€0.706507,804
€0.739+0.067+10.0%€0.675€0.779€0.6721,001,446
€0.672-0.021-3.0%€0.676€0.681€0.660243,333
€0.6930.0000.0%€0.692€0.704€0.667420,834
€0.693-0.016-2.3%€0.700€0.715€0.680439,488
Ticker
LS Exchange:A1CXBG
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LS Exchange
Currency
EUR

What changed lately

Latest news

All AB Science SA news

AB Science SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
29 in the last 12 months · 51 in all · newest Oct 12, 2026 · oldest 2025
Decks
21 decks · latest January 2026

Where AB Science SA is listed

ListingExchangeCountryCurrency
Euronext:AB · Home listingEuronextFranceEUR
LSE:0Q77LSEUnited KingdomEUR
LS Exchange:A1CXBG · This pageLS ExchangeGermanyEUR
OTC:ABSCFOTCUnited StatesUSD
Lang & Schwarz:A1CXBGLang & SchwarzGermanyEUR
gettex:A8DgettexGermanyEUR
Aquis:ABPAquisUnited KingdomEUR
Turquoise:ABPTurquoiseUnited KingdomEUR
Aquis:ABPAquisUnited KingdomEUR
Dusseldorf:A8DDusseldorfGermanyEUR
Frankfurt:A8DFrankfurtGermanyEUR
Hamburg:A8DHamburgGermanyEUR
Munich:A8DMunichGermanyEUR
Stuttgart:A8DStuttgartGermanyEUR
Tradegate:A8DTradegateGermanyEUR

Valuation

EV/sales 39.2× against a median of 128×: 3rd lowest of 5 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
€46.05M EUR
P/E
Loss
EV/sales
39.2×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
61.3%
Operating margin
−103.7%
Net margin
−132.6%
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
AB Science SA · EURONEXT:ABUS$55.19MUS$50.54Mn/a39.2×n/an/a−132.6%n/an/a
Kazia Therapeutics Ltd · NASDAQ:KZIAUS$56.22MUS$10.36Mn/a373×n/a1.8×n/a0.0×2.31
OKYO Pharma Limited · NASDAQ:OKYOUS$56.15MUS$35.56Mn/an/an/a4.5×n/a0.0×1.02
Gwo Xi Stem Cell Applied Technology Co., Ltd. · TPEX:6704US$55.77MUS$51.65Mn/a9.1×n/a2.5×−43.0%0.3×n/a
Cognition Therapeutics, Inc. · NASDAQ:CGTXUS$55.37MUS$25.10Mn/an/an/a1.9×n/a0.0×2.28
EyeGene, Inc. · KRX:185490US$55.23MUS$26.50Mn/a8.0×n/a1.5×−391.5%0.0×n/a
Azora Therapeutics, Inc. · NASDAQ:AZRUS$55.00MUS$33.00Mn/an/an/an/an/an/a1.00
Island Pharmaceuticals Ltd · ASX:ILAUS$54.84MUS$46.32Mn/a248×n/a6.2×n/a0.0×n/a
Anavex Life Sciences Corp. · NASDAQ:AVXLUS$54.83M−US$63.50Mn/an/an/a0.5×n/a0.0×2.39
Nordicus Partners Corp · OTC:NORDUS$54.44MUS$54.44Mn/an/an/a0.9×n/a0.0×0.45
Boundless Bio, Inc. · NASDAQ:BOLDUS$53.61M−US$9.28Mn/an/an/a0.9×n/a0.0×0.65
Median of the othersUS$55.11MUS$29.75M128×1.8×−217.3%0.0×1.02

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
4.49 EUR · Analysts' mean
EPS, year to Dec 2026
-0.15 · 1 analyst

Team and board

Officers

OfficerRole
Stéphane LEDERMANNChairman and Chief Executive Officer
Laurent GUYChief Financial Officer
Christian FASSOTTEGlobal Chief Medical Officer

Board

DirectorRole
Stéphane LEDERMANNChairman and Chief Executive Officer

Decks

DeckKindSlidesDate
Investor Presentation (January 2026)Investor deck33 slidesJanuary 2026
Investor Presentation (March 2025)Investor deck59 slidesMarch 2025
Corporate Update (December 2024)Corporate update35 slidesDecember 2024
Investor Presentation (July 2024)Investor deck46 slidesJuly 2024
Investor Presentation (April 2024)Investor deck37 slidesApril 2024
Investor Presentation (February 2023)Investor deck28 slidesFebruary 2023
Corporate Update (February 2022)Corporate update27 slidesFeb 28, 2022
Investor Presentation (January 2022)Investor deck60 slidesJanuary 2022
Investor Presentation (October 2021)Investor deck61 slidesOctober 2021
Technical Presentation (May 2021)Technical28 slidesMay 25, 2021
All 21 decks
DeckKindSlidesDate
AB Science Webconference: Masitinib in Pancreatic Cancer (December 2020)Conference22 slidesDec 11, 2020
Investor Presentation (December 2020)Investor deck49 slidesDecember 2020
MSVirtual2020 (ACTRIMS-ECTRIMS) (November 2020)Conference16 slidesNovember 2020
Investor Presentation (September 2020)Investor deck35 slidesSeptember 2020
Corporate Update (May 2020)Corporate update23 slidesMay 11, 2020
Technical Presentation (March 2020)Technical36 slidesMar 6, 2020
Investor Presentation (January 2020)Investor deck39 slidesJanuary 2020
AB Science Webconference: Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids (December 2019)Conference27 slidesDec 2, 2019
Corporate Update (November 2019)Corporate update46 slidesNov 20, 2019
Investor Presentation (2018)Investor deck17 slidesOct 4, 2018
Advances in Alzheimer Therapy (AAT) 2016Conference34 slidesMarch 2016

Open Decks

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares with share warrants attached (ABSA)
Closed: €14.2M raised · €0.61 a share · 1 warrant at €1 for 60 months
Buyers: Existing long-term investor (EUR 12 million); Stéphane Ledermann
Insiders: The CEO, Stéphane Ledermann, also contributed to the financing
Use of proceeds: Fund R&D programs, mainly AB8939 in acute myeloid leukemia, masitinib in ALS, and nearer-term value-creation projects
Aug 10, 2026US$16.4M
Private placement of new ordinary shares with share warrants attached (ABSA)
Announced: €3.2M · €0.94 a share · Warrants at €1.3 for 48 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Use of proceeds: Finance ongoing activities, with a focus on the clinical development of the AB8939 program
Apr 29, 2026US$3.74M
Private placement of new ordinary shares with share warrants attached (ABSAs)
Closed: €2.8M raised · €1.13 a share · Warrants at €1.72 for 60 months
Use of proceeds: Finance ongoing activities, focusing on clinical development of AB8939: finish phase 1 and launch an AML expansion study
Oct 17, 2025US$3.27M
Private placement of new ordinary shares with share warrants attached (ABSAs)
Closed: €2.55M raised · €1.12 a share · Warrants at €1.71 for 60 months
Use of proceeds: To finance ongoing activities, with a focus on the clinical development of the AB8939 program
Aug 4, 2025US$2.94M
Private placement of new ordinary shares with share warrants attached (ABSAs)
Closed: €1.93M raised · €1.17 a share · Warrants at €1.78 for 60 months
Use of proceeds: Finance ongoing activities, with a focus on clinical development of the AB8939 program
Jul 8, 2025US$2.25M
Private placement of new shares
Closed: €1.8M in the latest tranche · €1.17 a share · Warrants at €1.79 for 60 months · Maxim Group, LLC
Dealers: Maxim Group, LLC (lead)
Use of proceeds: Strengthens the cash position and covers financing needs in 2025 and beyond the next 12 months
May 23, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.17M1.07M970.0K958.0K1.61M1.58M1.57M1.70M1.74M1.51M
Cost of revenue454.0K-176.0K383.0K31.0K111.0K69.0K181.0K248.0K121.0K453.0K
Gross profit720.0K1.25M587.0K927.0K1.50M1.51M1.39M1.45M1.62M1.05M
Research and development2.09M3.94M13.9M13.3M11.2M12.8M15.6M26.9M26.7M27.9M
Selling, general and administrative1.39M1.81M3.02M1.87M3.58M2.64M2.26M2.39M2.27M2.48M
Operating income-1.22M-6.08M-13.4M-15.9M-13.8M-14.7M-17.5M-28.9M-28.4M-30.2M
Depreciation and amortization3.00K667.0K2.27M805.0K886.0K1.15M853.0K669.0K436.0K611.0K
EBITDA-1.21M-5.42M-11.2M-15.1M-12.9M-13.6M-16.6M-28.3M-28.0M-29.6M
Interest expense1.41M1.23M3.96M3.41M56.0K157.0K17.0K00474.0K
Income before tax-3.41M-7.83M-12.0M-13.6M-14.4M-15.0M-21.7M-26.1M-27.1M-27.7M
Income tax-1.86M-2.32M-1.94M4.00K36.0K8.00K4.00K4.00K6.00K-11.0K
Net income-1.56M-7.83M-10.0M-13.6M-14.5M-15.0M-21.7M-26.1M-27.1M-27.7M
Earnings per share, basic-0.03-0.15-0.20-0.29-0.30-0.34-0.55-0.69-0.75-0.78

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents10.2M7.99M6.07M7.27M8.72M20.7M5.70M11.6M38.8M19.8M
Short-term investments000006.00M10.0M0
Receivables3.49M827.0K236.0K12.5M8.36M4.86M8.16M236.0K449.0K428.0K
Inventory151.0K184.0K336.0K456.0K141.0K79.0K230.0K153.0K159.0K134.0K
Current assets14.2M14.5M19.4M20.9M18.2M26.3M14.1M20.7M48.6M36.1M
Property, plant and equipment899.0K785.0K1.27M1.59M1.82M2.17M153.0K171.0K214.0K
Total assets24.5M23.2M25.5M23.8M21.3M29.7M17.7M22.5M50.6M38.0M
Accounts payable9.30M6.00M11.1M7.36M11.4M13.3M15.0M15.0M15.5M16.6M
Current liabilities14.8M20.4M18.7M23.1M17.5M22.6M19.5M19.2M18.7M20.3M
Long-term debt17.9M14.0M16.6M18.6M6.69M11.1M10.2M9.34M9.33M21.7M
Total debt4.24M18.5M19.1M28.3M15.1M19.9M14.4M8.21M11.1M12.4M
Total liabilities34.3M46.9M46.5M59.5M44.5M49.2M44.6M37.5M39.9M42.7M
Shareholders' equity-17.2M-23.8M-21.0M-35.7M-23.2M-19.5M-26.8M-15.0M10.7M-4.71M
Shares outstanding61.2M52.2M49.7M47.1M47.5M44.2M39.4M37.8M36.0M35.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-4.29M525.0K-16.9M-17.5M-17.2M-13.5M-15.2M-26.8M-22.9M-33.5M
Capital spending-282.0K-155.0K-345.0K-644.0K-564.0K-370.0K-390.0K-484.0K-503.0K-524.0K
Free cash flow-4.57M370.0K-17.2M-18.1M-17.7M-13.9M-15.5M-27.3M-23.4M-34.0M
Cash from investing-224.0K-136.0K-614.0K-360.0K-590.0K-277.0K-432.0K-490.0K-495.0K5.36M
Cash from financing6.69M1.53M16.3M16.4M5.84M28.7M9.73M61.0K42.4M32.3M
Share buybacks3.89M11.5M4.00K4.16M22.7M9.74M61.0K42.4M32.4M
Change in cash2.19M1.92M-1.20M-1.45M-11.9M15.0M-5.87M-27.2M19.0M4.08M

Open Financials

Filings

Open Filings

Cap table

Built by 6ix from AB Science SA’s releases · as of Aug 12, 2026

Common shares
96,530,783
Fully diluted
119,809,475

Fully diluted

LineSharesAs of
Common shares96,530,783Aug 10, 2026
Warrants23,278,692Aug 12, 2026

Warrants and options

Lot
Warrants · €1.00 · expire about Aug 2031
Warrants · €1.72 · expire about Oct 2030
Warrants · €1.71 · expire about Aug 2030
Warrants · €1.78 · expire about Jul 2030
Warrants · €1.79 · expire about May 2030

Share count over time

CountShares
Aug 10, 202696,530,783

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Christian FASSOTTEGlobal Chief Medical Officer · Since at least Nov 5, 2026
Laurent GUYChief Financial Officer · Since at least Nov 5, 2026
Stéphane LedermannChairman and Chief Executive Officer · Since at least Oct 9, 2026

Open People

Log in to ask 6ix AI your own questions about AB Science SA.